Seeking Alpha

The FDA rejects Merck's (MRK) new drug application for ridaforolimus, a bone cancer treatment,...

The FDA rejects Merck's (MRK) new drug application for ridaforolimus, a bone cancer treatment, saying further trials are needed to assess the drug’s effectiveness and safety. MRK acquired the rights to the drug from Ariad Pharmaceuticals (ARIA) in 2010, which would receive $25M plus royalty payments if the drug is approved.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs